Recent Articles

August 24, 2016 2:02 pm
Lee Schalop, Chief Business Officer and Josh Allen, Vice President, Research and Development; Oncoceutics Inc.
There are currently no approved cancer drugs that work by blocking a G-protein-coupled receptor (GPCR). Dopamine receptors have an effect on cancer but this connection raises a few key questions.
August 24, 2016 3:00 pm
Callum Dew, Associate Analyst, GBI Research
The global market for diabetes mellitus and obesity is set to rise from $70.8 billion in 2015 to $163.2 billion by 2022.
August 24, 2016 12:20 pm
Ryan Bushey
Pfizer made another impressive acquisition this week.
August 22, 2016 4:09 pm
Ryan Bushey
Currently, there are no dedicated vaccines for this condition, but a new partnership hopes to change that.
August 22, 2016 4:30 pm
Ryan Bushey
Eli Lilly and AstraZeneca gained an advantage in the race to develop a BACE inhibitor to treat Alzheimer’s.
August 22, 2016 11:22 am
Ryan Bushey
The opioid epidemic sweeping the country is becoming a difficult problem to solve.
August 19, 2016 3:00 pm
Yasser Mushtaq, Senior Analyst, GBI Research
There are only two of these products on the market – Kalydeco and Orkambi – both of which were developed by Vertex.
August 19, 2016 8:29 am
The vast reforms seen throughout Turkey’s pharmaceutical market mean there are a number of opportunities open to pharmaceutical manufacturers.
August 17, 2016 3:00 pm
Fiona Chisolm, Analyst, GBI Research
The rheumatoid arthritis market is highly lucrative and significant advances in the understanding of the disease have greatly improved treatment options for a large number of patients over the past two decades.
Ryan Bushey
Johnson & Johnson could soon have another blockbuster on their hands.
Subscribe to Drug Discovery & Development